Loading... (0%)
About liver disease

TGFTX1 program

Our TGFTX1 preclinical program is focused on the discovery and development of innovative drug candidates targeting RORγt, a key nuclear receptor that directs IL-17 mediated immunity. In particular, we focus on treating psoriasis or respiratory conditions such as neutrophilic asthma, chronic obstructive pulmonary disease, or COPD, and the asthma-COPD overlap syndrome (ACOS).

RORγt inhibition represents a straightforward and efficient way to curb exacerbated IL-17-mediated immune responses with small molecule compounds that can act either systemically or locally (topical administration).

Topical RORγt drug candidate for the treatment of patients with mild-to-moderate psoriasis

Current status: pre-IND studies

This topical drug candidate is highly potent and selective and complies with a target product profile for topically delivered drugs. Additionally, we have completed several regulatory pre-IND studies that are required for topically administered agents.

In-vivo studies showed that this compound improves both disease score and skin histology in a classical mouse model of psoriasis.

Inhaled RORγt drug candidate for the treatment of respiratory diseases

Current status: in vivo proof-of-concept studies

This drug candidate is highly potent and selective and complies with target product profile for delivery by inhalation. It was optimized to have very high aqueous solubility, necessary for inhalable medicines to be applied in a form of powder.

In-vitro studies showed that this particular compound inhibits with high potency IL-17 release in human primary lymphocytes.

To further these programs, we plan to leverage the expertise of specialized pharmaceutical companies with already established franchises in dermatology and/or respiratory diseases through collaborations or other strategic alliances that we may enter into in the future.

ut Lorem leo. commodo ut felis sem, facilisis id,